Sign in
4

Changes in Ownership

Avalo Therapeutics, Inc. Filed Acc 0001104659-18-021354

Chief Executive Officer acquired 400,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Greenleaf Peter · Chief Executive Officer

Table I: Non-derivative

1 line
Date Transaction Shares Owned after D/I
2018-03-27 Grant or award : show line 1 in the form +400,000 400,000 D

Table II: Derivative

2 lines
Date Transaction Shares Exercise Expires Underlying Owned after D/I
2018-03-27 Grant or award : show line 2 in the form Employee Stock Option (Right to Buy) +500,000 $4.24 2028-03-27 500,000 500,000 D
2018-03-27 Grant or award : show line 3 in the form Employee Stock Option (Right to Buy) +500,000 $4.24 2028-03-27 500,000 500,000 D
Loading xslF345X03/a4.xml…